Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
This study has been completed.
Study NCT00056446   Information provided by Novartis

First Received on March 13, 2003.   Last Updated on November 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Neoplasms
Colonic Neoplasms
Rectal Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
Vatalanib
Additional drug interventions recognized in this trial
Leucovorin
Levoleucovorin
Oxaliplatin
More general drug interventions related to this trial
Antidotes
Antineoplastic Agents
Enzyme Inhibitors
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Protein Kinase Inhibitors
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Novartis Pharmaceuticals
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services